Saraswat et al. designed a dual lipid nanocarrier approach to co-deliver a PTEN plasmid and the BRD4-targeting PROTAC (ARV-825) for synergistic suppression of c-Myc-driven, drug-resistant melanoma [95]. Here, MYC is linked to melanoma.